Immunohistochemical detection of stem cell markers, transcription factors and PD-L1 in malignant gliomas in adults patients
- Authors: Sulin K.A1, Galkovsky B.E1, Petrov A.A1, Ryzhkova D.V1, Krasnoshlyk P.V1, Gulyaev D.A1, Makarov I.A1, Gaycova O.N1, Sidorin V.S1, Mitrofanova L.B1
-
Affiliations:
- Almazov National Medical Research Centre
- Issue: Vol 16, No 4 (2021)
- Pages: 42-50
- Section: Articles
- URL: https://genescells.ru/2313-1829/article/view/121901
- DOI: https://doi.org/10.23868/202112005
Cite item
Abstract
Full Text

About the authors
K. A Sulin
Almazov National Medical Research Centre
Email: lubamitr@yandex.ru
St. Petersburg, Russia
B. E Galkovsky
Almazov National Medical Research Centre
Email: lubamitr@yandex.ru
St. Petersburg, Russia
A. A Petrov
Almazov National Medical Research Centre
Email: lubamitr@yandex.ru
St. Petersburg, Russia
D. V Ryzhkova
Almazov National Medical Research Centre
Email: lubamitr@yandex.ru
St. Petersburg, Russia
P. V Krasnoshlyk
Almazov National Medical Research Centre
Email: lubamitr@yandex.ru
St. Petersburg, Russia
D. A Gulyaev
Almazov National Medical Research Centre
Email: lubamitr@yandex.ru
St. Petersburg, Russia
I. A Makarov
Almazov National Medical Research Centre
Email: lubamitr@yandex.ru
St. Petersburg, Russia
O. N Gaycova
Almazov National Medical Research Centre
Email: lubamitr@yandex.ru
St. Petersburg, Russia
V. S Sidorin
Almazov National Medical Research Centre
Email: lubamitr@yandex.ru
St. Petersburg, Russia
L. B Mitrofanova
Almazov National Medical Research Centre
Email: lubamitr@yandex.ru
St. Petersburg, Russia
References
- Ostrom Q.T., Gittleman H., Fulop J. et al. CBTRUS Statistical Report: Primary Brain and Central Nervous System Tumors Diagnosed in the United States in 2008-2012. J. Neurooncol. 2015; 17(4): 1-62.
- Darlix A., Zouaoui S., Rigau V. et al. Epidemiology for primary brain tumors: a nationwide population-based study. J. Neurooncol. 2017; 131(3): 525-46.
- Stupp R., Hegi M.E., Mason W.P. et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol. 2009; 10(5): 459-66.
- Stupp R., Mason W.P., van den Bent M.J. et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N. Engl. J. Med. 2005; 352(10): 987-96.
- Reardon D.A., Brandes A.A., Omuro A. et al. Effect of Nivolumab vs Bevacizumab in Patients With Recurrent Glioblastoma: The CheckMate 143 Phase 3 Randomized Clinical Trial. JAMA Oncol. 2020; 6(7): 1003-10.
- Nabors L.B., Portnow J., Ammirati M. et al. NCCN Guidelines Insights: Central Nervous System Cancers, Version 1.2017. J. Natl.Compr. Canc.Netw. 2017; 15(11): 1331-45.
- Lathia J.D., Mack S.C., Mulkearns-Hubert E.E. et al. Cancer stem cells in glioblastoma. Genes Dev. 2015; 29(12): 1203-17.
- Lim M., Xia Y., Bettegowda C. et al. Current state of immunotherapy for glioblastoma. Nat. Rev. Clin. Oncol. 2018; 15(7): 422-42.
- Louis D.N., Perry A., Wesseling P. et al. The 2021 WHO Classification of Tumors of the Central Nervous System: a summary. J. Neurooncol. 2021; 23(8): 1231-51.
- Miraglia S., Godfrey W., Yin A.H. et al. A novel five-transmembrane hematopoietic stem cell antigen: isolation, characterization, and molecular cloning. Blood 1997; 90(12): 5013-21.
- Bryukhovetskiy I., Ponomarenko A., Lyakhova I. et al. Personalized regulation of glioblastoma cancer stem cells based on biomedical technologies: From theory to experiment (Review).Int. J. Mol. Med. 2018; 42(2): 691-702.
- Schmitz M., Temme A., Senner V. et al. Identification of SOX2 as a novel glioma-associated antigen and potential target for T cell-based immunotherapy. Br.J. Cancer 2007; 96(8): 1293-301.
- Levy A., Blacher E., Vaknine H. et al. CD38 deficiency in the tumor microenvironment attenuates glioma progression and modulates features of tumor-associated microglia/macrophages. J. Neurooncol. 2012; 14(8): 1037-49.
- Aulakh S., Manna A., Schiapparelli P. et al. CD38-targeted therapy in glioblastoma: A step foreward. J. of Clinical Oncology 2018; 36: 15.
- Гальковский Б.Э., Митрофанова Л.Б., Лахина Ю.С. и соавт. Иммуногистохимическое исследование белков Prox1, CD133 и CD38 в глиобластомах вентрикулярно-субвентрикулярной зоны и их влияние на продолжительность жизни пациентов. Ученые записки Санкт-Петербургского государственного медицинского университета имени академика И.П. Павлова 2020; 27(1): 75-85.
- Zhang N., Wei P., Gong A. et al. FoxM1 promotes β-catenin nuclear localization and controls Wnt target-gene expression and glioma tumorigen-esis. Cancer Cell 2011; 20(4): 427-42.
- Chen L.P., Zhang N.N., Ren X.Q. et al. miR-103/miR-195/miR-15b Regulate SALL4 and Inhibit Proliferation and Migration in Glioma. Molecules 2018; 23(11): 2938.
- Wu Y., Sun B., Shi W. et al. OCT4 is up-regulated by DNA hypomethylation of promoter in recurrent gliomas. Neoplasma 2016; 63(3): 378-84.
- Hao C., Chen G., Zhao H. et al. PD-L1 Expression in Glioblastoma, the Clinical and Prognostic Significance: A Systematic Literature Review and Meta-Analysis. Front. Oncol. 2020; 10: 1015.
- Berghoff A.S., Kiesel B., Widhalm G. et al. Programmed death ligand 1 expression and tumour-infiltrating lymphocytes in glioblastoma. J. Neurooncol. 2015; 17(8): 1064-75.
- Zbinden M., Duquet A., Lorente-Trigos A. et al. NANOG regulates glioma stem cells and is essential in vivo acting in a cross-functional network with GLI1 and p53. EMBO J. 2010; 29: 2659-74.
- Kuciak M., Mas C., Borges I. et al. Chimeric NANOG repressors inhibit glioblastoma growth in vivo in a context-dependent manner. Sci. Rep. 2019; 9(1): 3891.
- Luo W., Gao F., Li S. et al. FoxM1 Promotes Cell Proliferation, Invasion, and Stem Cell Properties in Nasopharyngeal Carcinoma. Front. Oncol. 2018; 8: 483.
- Gong A., Huang S. FoxM1 and Wnt/-Catenin Signaling in Glioma Stem Cells. Cancer Research 2012; 72(22): 5658-62.
- Гальковский Б.Э., Митрофанова Л.Б., Гуляев Д.А. и соавт. Иммуногистохимическое исследование транскрипционных факторов NeuroD1, Prox1, FoxM1, соматостатиновых, а также CXCR4- и CD38-рецепторов в глиобластомах в целях разработки новых подходов для таргетной терапии. Молекулярная медицина 2020; 18(2): 44-50.
- Singh S.K., Hawkins C., Clarke I.D. et al. Identification of human brain tumour initiating cells. Nature 2004; 432(7015): 396-401.
- Liu G., Yuan X., Zeng Z. et al. Analysis of gene expression and chemore-sistance of CD133+ cancer stem cells in glioblastoma. Mol. Cancer 2006; 5: 67.
- Zhang Q., Xu B., Chen J. et al. Clinical significance of CD133 and Nestin in astrocytic tumor: The correlation with pathological grade and survival. J. Clin. Lab. Anal. 2020; 34(3): 23082.
- Zhang M., Song T., Yang L. et al. Nestin and CD133: valuable stem cell-specific markers for determining clinical outcome of glioma patients. J. Exp. Clin. Cancer Res. 2008; 27(1): 85.
- Ludwig K., Kornblum H.I. Molecular markers in glioma. J. Neurooncol. 2017; 134(3): 505-12.
- Dahlrot R.H., Hermansen S.K., Hansen S. et al. What is the clinical value of cancer stem cell markers in gliomas? Int. J. Clin. Exp. Pathol. 2013; 6(3): 334-48.
- Bradshaw A., Wickremsekera A., Tan S.T. et al. Cancer Stem Cell Hierarchy in Glioblastoma Multiforme. Front. Surg. 2016; 3: 21.
- Xie L., Zeng X., Hu J. et al. Characterization of Nestin, a Selective Marker for Bone Marrow Derived Mesenchymal Stem Cells.Int. J. Stem Cells 2015; 2015: 762098.
- Blacher E., Ben Baruch B., Levy A. et al. Inhibition of glioma progression by a newly discovered CD38 inhibitor.Int. J. Cancer 2015; 136(6): 1422-33.
- Alak M., Sonikpreet A., Asher C. et al. Therapeutic targeting of CD38 enhances temozolomide activity in glioblastoma cells and modulates their tumor microenvironment by eliciting an enhanced CD8+ T cell response. J. of Immunology 2020; 204(1): 91.
- Yang J., Gao C., Chai L. et al. A Novel SALL4/OCT4 Transcriptional Feedback Network for Pluripotency of Embryonic Stem Cells. PLoS ONE 2010; 5(5): 10766.
- Xue S., Hu M., Iyer V. et al. Blocking the PD-1/PD-L1 pathway in glioma: a potential new treatment strategy. J. Hematol. Oncol. 2017; 10(1): 81.
- Vora P., Venugopal C., Salim S.K. et al. The Rational Development of CD133-Targeting Immunotherapies for Glioblastoma.Int. J. Stem Cells 2020; 26(6): 832-44.
